William K. Oh, MD

Experts outline evolving EP-NEC care: smarter combo therapies, DLL3 targets, precise pathology, and why early clinical trials matter.

This episode, titled ‘Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies,’ featured panelists discussing the following critical questions

Learn how tumor and liquid biopsy biomarker tests are ordered, why results take weeks, and how insurance rules can delay cancer treatment.

Learn how tumor and liquid biopsy testing fits care—plus insurance hurdles, turnaround delays, and the push for faster NGS results.

Explore evolving biomarker testing for rare neuroendocrine carcinomas—NGS, MSI/TMB, and emerging DLL3 targets guiding new trials.

Experts explain evolving biomarker testing for rare neuroendocrine carcinomas, from NCCN gaps to DLL3 and NGS, guiding trials and treatment.

Learn how aggressive neuroendocrine carcinoma disrupts daily life—and why rapid treatment, strong caregiver support, and navigation resources matter.

Experts warn extrapulmonary neuroendocrine carcinomas are often missed; faster pathology, rapid referrals, and early treatment improve survival.

Rare neuroendocrine carcinomas outside the lung often go missed; expert pathology and rapid referrals enable earlier treatment and better outcomes.

Learn how rare neuroendocrine cancers are diagnosed, why pathology and Ki-67 guide care, and how teams coordinate chemo, trials, support.

Experts unpack neuroendocrine carcinoma vs tumors, key pathology markers, and high-risk features shaping prognosis and treatment decisions.